SHILPAMED Shilpa Medicare Ltd Product Launches Announcement 2025 - CDSCO Approval Shilpa Medicare has received CDSCO approval for its IND Nor-Ursodeoxycholic acid Tablets for treating Non-Alcoholic Fatty Liver Disease (NAFLD), with promising Phase 3 trial results showing 83.3% improvement in liver fibrosis after 24 weeks of treatment in 165 patients..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Shilpa Medicare Ltd